Protagonist Therapeutics (PTGX) Accumulated Depreciation & Amortization (2017 - 2025)
Historic Accumulated Depreciation & Amortization for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $7.9 million.
- Protagonist Therapeutics' Accumulated Depreciation & Amortization rose 1459.3% to $7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year increase of 1459.3%. This contributed to the annual value of $7.0 million for FY2024, which is 1284.89% up from last year.
- According to the latest figures from Q3 2025, Protagonist Therapeutics' Accumulated Depreciation & Amortization is $7.9 million, which was up 1459.3% from $7.6 million recorded in Q2 2025.
- Protagonist Therapeutics' Accumulated Depreciation & Amortization's 5-year high stood at $7.9 million during Q3 2025, with a 5-year trough of $4.5 million in Q1 2022.
- For the 5-year period, Protagonist Therapeutics' Accumulated Depreciation & Amortization averaged around $6.3 million, with its median value being $6.4 million (2023).
- Within the past 5 years, the most significant YoY rise in Protagonist Therapeutics' Accumulated Depreciation & Amortization was 2137.02% (2023), while the steepest drop was 643.85% (2023).
- Over the past 5 years, Protagonist Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $5.8 million in 2021, then rose by 15.0% to $6.7 million in 2022, then fell by 6.44% to $6.2 million in 2023, then increased by 12.85% to $7.0 million in 2024, then rose by 12.85% to $7.9 million in 2025.
- Its Accumulated Depreciation & Amortization stands at $7.9 million for Q3 2025, versus $7.6 million for Q2 2025 and $7.3 million for Q1 2025.